FDA posts Provenge documents

Data submitted by Dendreon (DNDN) on Provenge sipuleucel-T "tend to support a finding of clinically meaningful increased survival, but doubts remain about the persuasiveness of the efficacy data,"

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE